DEVELOPMENT OF DRUG DELIVERY SYSTEMS BASED ON NEW BIO-S*

Information

  • Research Project
  • 6515239
  • ApplicationId
    6515239
  • Core Project Number
    R43CA092817
  • Full Project Number
    5R43CA092817-02
  • Serial Number
    92817
  • FOA Number
    PAR-00-030
  • Sub Project Id
  • Project Start Date
    9/7/2001 - 23 years ago
  • Project End Date
    8/31/2004 - 20 years ago
  • Program Officer Name
    FU, YALI
  • Budget Start Date
    9/1/2002 - 22 years ago
  • Budget End Date
    8/31/2004 - 20 years ago
  • Fiscal Year
    2002
  • Support Year
    2
  • Suffix
  • Award Notice Date
    7/19/2002 - 22 years ago
Organizations

DEVELOPMENT OF DRUG DELIVERY SYSTEMS BASED ON NEW BIO-S*

DESCRIPTION (provided by applicant): The development of new treatment modalities for neoplastic diseases has coincided with the invention of in vivo drug delivery systems. The in vivo drug delivery systems can, in principal, ameliorate the harmful side effect of antineoplastic agents. Over the past 4 years, ECOSYNTHETIX has developed a series of biobased products including new sugar based vinyl macromers that serve as building blocks for a variety of polymer technologies. These sugar macromers have unusual properties that have been exploited in the area of water-based copolymers used in applications such as environmentally friendly pressure sensitive adhesives and water-based inks. ECOSYNTHETIX has optimized the process for incorporation of the sugar macromers into various copolymers and novel cross-linked starch nanoparticles. As part of this proposal, a process is proposed for production of novel macromer/starch hybrid materials that are inherently non-toxic. The hybrid materials will be developed for drug delivery systems to be used in the treatment of cancer. The hybrid nanospheres will be used to encapsulate several different antineoplastic agents including camptothecin derivatives and BCNU. The starch hybrids will be cast as thin films with the incorporated drug. The release profiles of the thin films will be determined. The physical properties of the drug-nanosphere complex will be studied. In addition, the release profiles of the drug-nanosphere complexes will be determined under physiological conditions. PROPOSED COMMERCIAL APPLICATIONS: Starch nanosphere hybrid particles represent a new class of particles to be used as drug delivery systems for treatment of manner. These nanosphere particles could potentially extend the use of antitumor agents such as namtothecin derivatives, BCNU.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    140150
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:140150\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ECOSYNTHETIX, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    LANSING
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    48910
  • Organization District
    UNITED STATES